Literature DB >> 33135463

Efficacy of ropivacaine versus bupivacaine in preventing peribulbar block failure: A meta-analysis.

Denismar B Miranda1, Marcela Ma Bastos1, Catia S Govêia2, Rodrigo E Silva1, Francisco W Rodrigues1.   

Abstract

PURPOSE: Peribulbar block is considered a standard of care in ophthalmological practice due to its easy execution and minor complications. There is a paucity of studies confirming efficacy between ropivacaine and bupivacaine for this specific technique. We evaluated the efficacy of ropivacaine or bupivacaine in preventing total or partial peribulbar block failure in ophthalmic surgeries.
METHODS: Meta-analysis of randomized clinical trials, comparing patients submitted to ophthalmic surgeries under peribulbar anesthesia with ropivacaine and bupivacaine. We searched in different databases for articles published until March, 2018. Data on patients, anesthesia, procedures and akinesia were tabulated. After calculating the chi-square of heterogeneity, we adopted a random-effects model with DerSimonian-Laird test, as well as an odds ratio and a 95% confidence interval.
RESULTS: From the 310 articles identified, 21 studies were selected. The use of ropivacaine was considered a protective factor for ocular akinesia failure in peribulbar block when compared to bupivacaine (OR = 0.53, 95% CI = 0.35-0.81 and p value = 0.003).
CONCLUSIONS: In ophthalmic surgeries, ropivacaine in peribulbar anesthesia is associated with lower rate of block failure when compared to bupivacaine.

Entities:  

Keywords:  Peribulbar anesthesia; bupivacaine; meta-analysis; ophthalmic surgery; ropivacaine

Mesh:

Substances:

Year:  2020        PMID: 33135463     DOI: 10.1177/1120672120969370

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  1 in total

1.  The Effects of Periarticular Injection Cocktail in Postoperative Analgesia after Bilateral Unicompartmental Knee Arthroplasty.

Authors:  Ruizhu Wang; Jin Zhao; Xiaojing Guo; Binping Ji
Journal:  Comput Math Methods Med       Date:  2022-07-28       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.